PARP Inhibitors in Oncology
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Since hitting the market in 2015, drugs that target poly (ADP-ribose) polymerase (PARP) have transformed the clinical management of cancers harboring BRCA-mutations. As more PARP inhibitors have been commercialized, drug developers are turning their attention towards broadening drug labels and exploring combination strategies. This report covers the management of PARP inhibitors in the US, Europe, and Asia, focusing on efficacy and safety comparisons for approved products, current and future indications, and research and development strategies.
Scope
GlobalData’s PARP Inhibitors in Oncology combines key opinion leader insight with in-house analyst expertise and research to provide an insight-rich look at PARP inhibitors in the US, Europe, and Asia.
Components of the report include:
• Overview of PARP Inhibitors in Oncology – Background, mechanism of action, and clinical development of PARP inhibitors.
• Epidemiology Analysis – Which current and future disease spaces are relevant to PARP inhibitors.
• Marketed PARP Inhibitors – How the currently approved PARP inhibitors compare.
• Pipeline Assessment in the 8MM – What are the pipeline PARP inhibitor products in development in oncology.
• Key Players – What companies are developing PARP inhibitors in oncology.
• Research and Development Strategies – How are PARP inhibitor clinical trials being designed, and what combination strategies are being explored in the US, Europe, and Asia.
• Pricing, Reimbursement, and Regulatory Strategies – What current and future challenges face PARP inhibitors from a payer’s perspective.
Reasons to Buy
Develop business strategies by understanding the trends shaping and driving the PARP inhibitor market in the US, Europe, and Asia.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the portfolios of various competitors.
Identify areas of unmet need within the PARP inhibitor market to help drive research and development towards future market opportunities.
Gain insights to help plan and design your clinical trials.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Identify key pricing and reimbursement strategies.
AstraZeneca
BeiGene
Clovis Oncology
Jiangsu Hengrui Medicine Co.
Merck
Nerviano Medical Sciences
Oncology Venture
Pfizer
Sanofi
SyntheX
Tesaro
Table of Contents
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.